Where will the Omega Diagnostics share price go in July and beyond?

The Omega Diagnostics share price faces significant challenges says Rupert Hargreaves who is concerned about the company’s prospects.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Omega Diagnostics (LSE: ODX) share price has been on a rollercoaster ride over the past 12 months

Since the middle of July 2020, shares in the company have returned 19%. However, between the end of November and the beginning of March, the stock returned more than 100%. Between March and today, it has declined more than 50%. 

Nevertheless, despite this volatility, longer-term investors have been well rewarded. Investors who were savvy enough to buy at the end of March 2020 are currently sitting on gains of more than 500%, even with the recent volatility. 

And considering the recent volatility, I am beginning to wonder where the Omega Diagnostics share price will go next? 

Falling revenues

It is impossible to predict stock price movements in the short term. Still, in theory, equity prices should track the performance of their underlying businesses in the long run. 

When it comes to the Omega Diagnostics share price, it is challenging for me to say whether or not the company will continue to grow over the next few years. 

According to the group’s full-year results for the financial year to the end of March 2021, revenues decreased 11% to £8.7m. Due to lower sales, the company reported a statutory loss for the year of £2.1m. 

During the year, the testing group restructured into two primary divisions. Global Health covers HIV and Covid-19, and Health and Nutrition covers food sensitivities. 

Sales in the latter division fell last year as a result of the pandemic. Sales of food sensitivity products declined from £9.2m to £6.8m. 

Meanwhile, Global Health division sales increased to £1.9m for the year, up from £0.7m in the prior year. Revenues generated from Coivd-19 antibody tests accounted for all of the increase. Unfortunately, revenue from sales of these tests was lower than expected as “antibody testing was not adopted as widely as initially expected“.

To that end, the company is pursuing the development and sale of other rapid Covid tests. 

Omega Diagnostics share price challenges 

I think these results present a mixed picture of the group. The pandemic has hurt revenue overall, and sales of Covid tests have not been enough to cover the losses. 

As the pandemic continues to rumble on, it is not clear at this stage if that will change. The company itself has noted sales of testing kits are “very much dependent on the UK Government’s decisions as to test selection and timing“.

As such, I think the Omega Diagnostics share price could continue to drift lower. The market hates uncertainty, and right now, the company’s future is incredibly uncertain. It also remains at the mercy of the government. 

This makes it challenging for me to say whether or not the business will see improved profitability in the months ahead. And if I am struggling to analyse the company’s prospects, other investors may be as well.

Therefore, considering this uncertainty, I will not be buying the stock for my portfolio. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »